Nicotine lozenge is one of 181 small molecule programs targeting Nicotine Dependence. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
686 competitors in Lung Cancer
Nicotine lozenge
Tecentriq
Libtayo
Vizimpro
Talzenna
Folvite
Xylocaine
Immunotherapy
Paclitaxel and Carboplatin
Rilotumumab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details